MAPT and Alzheimer disease: Repeated CSF analyses in different laboratories using the cut-offs from the Amsterdam lab led to a change in biomarker classification of 12% of subjects based on CSF Aβ1-42, 1% based on t-tau, 22% based on p-tau, and 14% based on the AD profile (Table 2).